SOUTH SAN FRANCISCO, CA, January 3, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the appointment of Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer. Mr. Robertson brings more than twenty years of experience with corporate strategy, business operations, capital raising and M&A.

“We are excited to welcome Scott to the Star leadership team during this time of significant growth,” said Adam Rosenthal, PhD, Chief Executive Officer and Founder of Star Therapeutics.  “His extensive experience as a proven operator with a background in venture capital and investment banking will be invaluable as we continue to replicate our success in forming new portfolio companies and advancing them into the clinic.”  

Prior to joining Star Therapeutics, Mr. Robertson served as Chief Business Officer and Chief Financial Officer of DICE Therapeutics, where he contributed to corporate strategy, raised more than $700 million in private and public financings, and led the business development interactions that resulted in the acquisition of the company by Eli Lilly for $2.4 billion. Previously, at DuPont, he served as Business Development Director for DuPont Pioneer, with responsibility for mergers and acquisitions and strategic partnerships, and Portfolio Manager for DuPont Ventures. Prior to joining DuPont, Mr. Robertson was an investment professional at MPM Capital, a life sciences-dedicated venture capital fund, and earlier in his career, he was a member of the healthcare investment banking teams at Merrill Lynch & Co. and Thomas Weisel Partners. He holds a BS in Business Administration from the University of Southern California and an MBA from the Haas School of Business at the University of California, Berkeley.

“I’m very excited to join the Star Therapeutics team at a time of great momentum with its proven approach for translating novel biology into first-in-class antibody therapies.  I look forward to contributing my expertise to enable the company to deliver a wide range of powerful new medicines to patients,” said Mr. Robertson.